GlassScriptPhysician profile
Ahmed Abouesh
NPI 1487661120
$4,721.23
in general payments reported to CMS, 2019-2025
25 companies · $963 in 2025
The $963 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $888 · 2020: $459 · 2021: $214 · 2022: $490 · 2023: $956 · 2024: $753 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,671.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $702.53 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $556.68 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $475.01 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $418.32 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Allergan, INC. | $397.69 | 2019-2020 | |
| Bausch Health US, LLC | $329.85 | 2019-2025 | Aplenzin |
| Janssen Pharmaceuticals, INC | $280.96 | 2019-2025 | Invega Sustenna |
| Idorsia Pharmaceuticals US INC | $222.77 | 2022-2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $171.52 | 2019-2025 | Fanapt, Hetlioz |
| Corium, LLC | $148.78 | 2022-2024 | Azstarys |
| Neurocrine Biosciences, INC. | $131.70 | 2020-2025 | |
| Axsome Therapeutics, INC. | $125.08 | 2023-2025 | Auvelity |
| Lundbeck LLC | $122.27 | 2019-2024 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $120.73 | 2019-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $105.10 | 2019-2025 | Trintellix |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $72.70 | 2021-2023 | Belsomra |
| Tris Pharma INC | $70.64 | 2023-2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $64.85 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $58.31 | 2024 | |
| Indivior INC. | $41.98 | 2019-2021 | |
| Almatica Pharma LLC | $28.72 | 2025 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $22.64 | 2024 | Qelbree |
| Boston Scientific Corporation | $19.66 | 2023 | |
| Collegium Pharmaceutical, INC. | $18.17 | 2025 | Jornay Pm |
| Alfasigma USA, INC. | $14.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Abouesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.